RXi targets dermal cells with RNA delivery method

By Nick Taylor

- Last updated on GMT

Related tags: Scientific method, Pre-clinical development

RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.

Self delivering rxRNA (sd-rxRNA) has been developed to overcome the difficulties faced in administering RNA. RXi claims its preclinical research has demonstrated spontaneous cellular uptake into dermal cells and silencing of the targeted mRNA.

Pamela Pavco, vice president (VP) of pharmaceutical development at RXi, explained that the company is now trying to find the best candidates for particular applications. The goal is to move these candidates into non-clinical and then into clinical trials.

RXi is researching the use sd-rxRNA for both systemic and local administration.

Related topics: Ingredients, Delivery technologies

Related news

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers